Medpace Holdings, Inc. Common Stock

MEDPNASDAQ

Industrials · Services-commercial Physical & Biological Research

Market cap

$11.86B

Employees

6,300

Exchange

NASDAQ

Headquarters

CINCINNATI, OH

About Medpace Holdings, Inc. Common Stock

Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.

Industry

Services-commercial Physical & Biological Research

Sector

Industrials

Country

US

Website

www.medpace.com

MEDP news

Deadline Alert: Medpace Holdings, Inc. (MEDP) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Law firm Glancy Prongay Wolke & Rotter LLP is urging Medpace Holdings shareholders who suffered losses to join a securities fraud lawsuit against the company. The firm is investigating potential misconduct and encouraging affected investors to contact them before the legal deadline expires. Shareholders with losses may be eligible for compensation through the class action suit.

GlobeNewswire Inc. · May 15, 2026

Bronstein, Gewirtz & Grossman LLC Urges Medpace Holdings, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Law firm Bronstein, Gewirtz & Grossman has filed a class action lawsuit against Medpace Holdings, Inc., alleging investor harm. The firm is urging shareholders to take action and participate in the legal proceedings. This lawsuit represents an effort to recover damages for affected investors.

GlobeNewswire Inc. · May 15, 2026